Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 187Neoplasm Metastasis 150Neoplasms 141Leukemia, Myeloid, Acute 138Colorectal Neoplasms 131Breast Neoplasms 120Melanoma 95Ovarian Neoplasms 93Prostatic Neoplasms 89Recurrence 85Multiple Myeloma 83Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Myelodysplastic Syndromes 66Lymphoma, Non-Hodgkin 65Triple Negative Breast Neoplasms 57Glioma 57Stomach Neoplasms 54Endometrial Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Carcinoma, Renal Cell 49Brain Neoplasms 48Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 45Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 40Advanced Solid Tumors 40

Interventions

osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paclitaxel 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lethal Congenital Contracture Syndrome 2 × 90 days × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡